Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis

Leuk Res. 2008 Apr;32(4):673-4. doi: 10.1016/j.leukres.2007.08.008. Epub 2007 Sep 24.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzamides
  • Blast Crisis / drug therapy
  • Blast Crisis / genetics*
  • Dasatinib
  • Drug Resistance, Neoplasm / genetics*
  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Lymphocytes / drug effects
  • Lymphocytes / pathology
  • Middle Aged
  • Mutation / genetics*
  • Piperazines / administration & dosage
  • Polymerase Chain Reaction
  • Pyrimidines / administration & dosage
  • Remission Induction
  • Thiazoles / administration & dosage

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Thiazoles
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Dasatinib